Clinical Trials

Carcinoma, Hepatocellular

NCT07521852 2026-04-13

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

40 enrolled

Carcinoma, Hepatocellular, Neoplasms

NCT07506109 2026-04-07

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

49 enrolled

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT07331883 2026-03-27

Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)

35 enrolled

GastrointestinalGynecologic

Carcinoma, Hepatocellular

NCT05427487 2026-03-25

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Phase 1 Recruiting

70 enrolled

Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07492615 2026-03-25

A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

276 enrolled

Stomach Neoplasms

NCT06497985 2026-03-19

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

430 enrolled

Colorectal Neoplasms

NCT07474103 2026-03-16

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

49 enrolled

Rectal Neoplasms

NCT07468630 2026-03-12

TRIUNITE-08

106 enrolled

Colonic Neoplasms

NCT06530251 2026-03-04

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

280 enrolled

Carcinoma, Hepatocellular

NCT06353646 2026-02-13

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

28 enrolled

Pancreatic Neoplasms

NCT07398326 2026-02-09

Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer

37 enrolled

Colorectal Neoplasms

NCT05472948 2025-12-17

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

36 enrolled

Appendiceal Neoplasms, Neoplasm Metastasis

NCT07263386 2025-12-04

ARTEMIS-GC3

460 enrolled

Gastric Adenocarcinoma

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT07194005 2025-09-26

Remission

Stomach Neoplasms

NCT07186621 2025-09-22

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

286 enrolled

Carcinoma, Hepatocellular

NCT06577194 2025-09-19

A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

35 enrolled

Rectal Neoplasms

NCT06031285 2025-07-23

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

43 enrolled

Carcinoma, Hepatocellular

NCT06050317 2025-07-22

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

25 enrolled

Pancreatic Neoplasms

NCT06329973 2025-07-17

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

70 enrolled

Metastatic Gastroesophageal Junction Adenocarcinoma

NCT06356584 2025-06-26

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

62 enrolled

Colorectal Neoplasms

NCT07040098 2025-06-26

STELLARIII

228 enrolled

Locally Advanced Rectal Cancer (LARC)

NCT07025889 2025-06-18

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

55 enrolled

Stomach Neoplasms

NCT05357846 2025-06-12

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

422 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06794086 2025-05-13

SPARKLE-L

24 enrolled

Colorectal Neoplasms

NCT06956716 2025-05-04

Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

Advanced Intrahepatic Cholangiocarcinoma

NCT06925243 2025-04-22

Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

682 enrolled

Stomach Neoplasms

NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

221 enrolled

Locally Recurrent Rectal Cancer

NCT06860490 2025-03-26

HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

164 enrolled

Carcinoma, Hepatocellular

NCT05713994 2025-03-25

CCGLC-001

Recruiting

300 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06698757 2025-03-13

Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer

96 enrolled

Colorectal Neoplasms

NCT05010681 2025-02-27

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

25 enrolled

Cholangiocarcinoma

NCT05057052 2025-02-27

Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis

25 enrolled

Liver Metastases

NCT06841159 2025-02-24

iPULSAR-CRC

116 enrolled

Microsatellite Stable Metastatic Colorectal Cancer

NCT06456515 2025-02-17

Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC

Colorectal Neoplasms

NCT06333561 2025-02-06

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Recruiting

300 enrolled

Carcinoma, Hepatocellular

NCT06572813 2025-01-10

CISPD-7

63 enrolled

Pancreatic Neoplasms

NCT06204094 2025-01-07

CASINOs

37 enrolled

Rectal Neoplasms

NCT06761027 2025-01-07

mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer

29 enrolled

Pancreatic Neoplasms

NCT06730373 2024-12-31

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

110 enrolled

Stomach Neoplasms

NCT06558227 2024-12-16

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

90 enrolled

Carcinoma, Hepatocellular

NCT06718205 2024-12-05

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

112 enrolled

Esophageal Neoplasms

NCT06709417 2024-11-29

A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)

52 enrolled

Esophageal Squamous Cell Carcinoma

NCT06685276 2024-11-20

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

46 enrolled

Colorectal Cancer Metastatic

NCT06313190 2024-11-18

HSBRT2402

140 enrolled

Carcinoma, Hepatocellular

NCT06664996 2024-10-30

Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT

33 enrolled

Carcinoma, Hepatocellular

NCT05495152 2024-10-02

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

219 enrolled

Esophageal Squamous Cell Carcinoma

NCT06555471 2024-08-15

A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer

40 enrolled

Stomach Neoplasms

NCT06070636 2024-08-09

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma